TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting
Monday, April 28, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting
Price reaction · baseline $4.1 (2025-04-25 close) · 1 other HURA headline(s) in the window, move may be shared
day 0 close · peak
-3.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+457%
120-day peak, hindsight
Typical move
7%
average across 2 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
dalazatide
Phase 1 · Plaque Psoriasis
Full Press Release Details
TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting.